This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Alpha1-proteinase inhibitor human parenteral


Infusions of alpha1-proteinase inhibitor human.

Drugs List

  • alpha1-proteinase inhibitor 1000mg powder and solvent for solution for infusion
  • RESPREEZA 1000mg powder and solvent for solution for infusion
  • Therapeutic Indications


    Emphysema associated with alpha-1-antitrypsin deficiency

    Maintenance treatment to slow the progression of emphysema in adults with documented severe alpha 1-proteinase inhibitor deficiency, despite optimal treatment with other standard therapies.



    60mg/kg body weight administered once a week.


    Children under 18 years
    Immunoglobulin A deficiency with IgA antibodies

    Precautions and Warnings

    Patients over 65 years
    Restricted sodium intake

    Contains more than 1 mmol (23 mg) sodium per dose
    Advise ability to drive/operate machinery may be affected by side effects
    Treatment to be initiated and supervised by a specialist
    Derived from human plasma. Transmission of infective agents possible.
    Do not mix with other drugs or substances
    For single use only
    Must be given as an intravenous infusion
    Record name and batch number of administered product
    Vaccinate patients receiving this product against hepatitis A and B
    Monitor vital signs during initial stage of infusion
    Advise patient to report symptoms of allergic type hypersensitivity
    Consider discontinuing if suspected allergic reaction occurs
    Interrupt therapy/reduce infusion rate if infusion-related reactions occur
    Management of cases of shock should follow current medical standards
    Advise patient on giving up smoking

    Infusion rate

    During the first infusions, patient's clinical state, including vital signs, should be closely monitored throughout the infusion period. If any reaction takes place that might be related to the administration of human alpha 1-proteinase inhibitor, the rate of infusion should be decreased or the administration should be stopped, as required by the clinical condition of the patient. If symptoms subside promptly after stopping, the infusion may be resumed at a lower rate that is comfortable for the patient.

    Transmissible agents

    Standard safety measures to prevent infections resulting from the use of medicinal agents prepared from human blood or plasma include rigorous selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation and removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

    Pregnancy and Lactation


    Use alpha1-proteinase inhibitor human with caution during pregnancy.

    The manufacturer advises caution if alpha 1-proteinase inhibitor is used during pregnancy. Although there have been no studies in animal reproduction, as alpha1-proteinase inhibitor is an endogenous human protein, when given at the recommended dose it is unlikely to cause harm to the foetus.


    Alpha1-proteinase inhibitor human is contraindicated in breastfeeding.

    It is not known if alpha1-proteinase inhibitor human is excreted in human milk. The excretion of this agent has not been studied in animals. The manufacturer notes that a decision must be made whether to discontinue breastfeeding or to discontinue the therapy, taking into account the benefit of breastfeeding for the child and the benefit of the therapy for the woman.

    Side Effects

    Anaphylactic reaction
    Chest pain
    Eye swelling
    Facial swelling
    Hypersensitivity reactions
    Injection site reactions
    Lip enlargement
    Lymph node pain
    Pharyngeal oedema


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2020.

    Reference Sources

    Summary of Product Characteristics: Respreeza 1,000 mg powder and solvent for solution for infusion. CSL Behring UK Limited. October 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.